Daily Respiratory Research Analysis
Analyzed 230 papers and selected 3 impactful papers.
Summary
Across respiratory medicine, three papers stand out today: real‑world effectiveness of a bivalent RSV prefusion F vaccine over two seasons; a robust host blood 4‑gene signature that discriminates bacterial from nonbacterial lower respiratory tract infection in hospitalized adults; and an updated international consensus for point‑of‑care lung ultrasound. Collectively, they advance prevention, antimicrobial stewardship, and bedside imaging practice.
Research Themes
- Real-world vaccine effectiveness for respiratory virus prevention across seasons
- Host-response transcriptomic diagnostics to guide antibiotic stewardship in LRTI
- Updated consensus standards for point-of-care lung ultrasound in acute care
Selected Articles
1. Bivalent RSVpreF effectiveness against RSV-associated hospital or emergency department care over two seasons: a retrospective test-negative case control study.
In a large test-negative analysis across two RSV seasons in older adults, bivalent RSVpreF vaccination reduced RSV-associated hospital/ED encounters by 81% in the first season and 76% in the second. Protection persisted across age, frailty, risk factors, and RSV A/B, with relatively faster waning among immunocompromised adults.
Impact: This is the first real‑world estimate of seasonal durability of RSVpreF protection across two consecutive seasons and subgroups, directly informing vaccination timing and policy.
Clinical Implications: Results support seasonal RSV vaccination of adults ≥60 (including ≥75 and frail) with expectations of sustained protection into the following season, while highlighting the need for closer follow‑up or re‑dosing strategies in immunocompromised adults.
Key Findings
- VE against RSV-associated LRTD hospital/ED encounters: 81% (first season) and 76% (second season).
- Among 2023/24 vaccinees, VE was 87% at 0–<6 months and 77% at 6–18 months post-vaccination.
- Consistent protection across ≥75 years, risk factors, frailty, and RSV A/B subtypes.
- Immunocompromised adults showed more rapid VE decline (approx. 74% to 54% across seasons).
Methodological Strengths
- Test-negative design with multivariable adjustment to reduce bias from healthcare-seeking and co-circulating pathogens.
- Two-season evaluation enabling durability estimates across subtypes and high-risk subgroups in an integrated health system.
Limitations
- Observational design with potential residual confounding and misclassification.
- Single health system in Southern California; generalizability may be limited; industry funding (Pfizer) introduces potential conflict of interest.
Future Directions: Prospective evaluations of booster timing and immunogenicity in immunocompromised adults; comparative effectiveness across vaccine platforms and coadministration strategies.
BACKGROUND: Since RSV vaccine licensure in 2023, vaccine effectiveness (VE) studies demonstrated first season protection against severe RSV disease including RSV-related hospitalization/emergency department (ED) visits. Here, we estimate VE over two seasons, by RSV subtype, and for additional high-risk subgroups. METHODS: This retrospective test-negative case-control study included adults ≥60 years at Kaiser Permanente Southern California with lower respiratory tract disease (LRTD) or acute respiratory illness (ARI) hospitalization/ED during 24 November 2023─09 April 2024 and 05 November 2024─26 April 2025. In primary analyses, cases were RSV-positive and controls were negative for: RSV, SARS-CoV-2, influenza, and positive for a non-vaccine-preventable pathogen. Exposure was bivalent RSVpreF receipt ≥21 days before LRTD/ARI. VE was calculated using adjusted odds ratios from multivariable logistic regression. "First season after vaccination" includes events in the same RSV season as vaccination; "second season" includes events in 2024-25 among those vaccinated in 2023-24. FINDINGS: VE against RSV-associated LRTD hospitalizations/ED was 81% (95% CI: 68-89) and 76% (95% CI: 48-89) for first and second seasons after vaccination, respectively. Limiting to those vaccinated in 2023/2024, VE was 87% (95% CI: 37-97) 0-<6 and 77% (95% CI: 54-89) 6-18 months post-vaccination. Protection persisted across both seasons for adults aged ≥75 years, those with risk factors, frailty, immunocompromise, and by RSV A/B. VE in immunocompromised adults appeared to decrease more quickly: 74% (95% CI: 37-89) first season to 54% (95% CI: -48 to 85) second season. INTERPRETATION: RSVpreF vaccination was associated with protection against RSV-associated severe respiratory illness, overall and among the most vulnerable patients. VE appeared to decline modestly across two seasons in most populations, this finding was more pronounced among immunocompromised adults. Our VE estimates indicate potentially substantial public health benefit of RSV vaccination. FUNDING: This was a Pfizer-sponsored study.
2. Discriminating Bacterial from Nonbacterial Lower Respiratory Tract Infection within Clinical Subgroups of Hospitalized Adults.
A host-response 4‑gene blood signature maintained high discriminatory performance (AUC 0.77–0.94) for bacterial versus nonbacterial ARI across hospitalized adult subgroups, including those with pneumonia and chronic lung disease. It consistently outperformed subgroup‑specific models, supporting a single global classifier for bedside triage.
Impact: Validating a concise host transcriptomic tool across real‑world subgroups removes a key barrier to clinical translation and antibiotic stewardship in LRTI.
Clinical Implications: A single, blood-based host-response assay could support early antibiotic decisions across diverse hospitalized adults with ARI, potentially reducing unnecessary antibiotic usage and improving targeted therapy.
Key Findings
- Global 4-gene classifier achieved AUC 0.77–0.94 within all clinical subgroups, including pneumonia.
- Outperformed subgroup-specific gene signatures (AUC 0.57–0.90) in every comparison.
- Original cohort size was 504 hospitalized adults; prior global AUC was 0.90.
Methodological Strengths
- Pre-specified evaluation across clinically relevant subgroups (pneumonia, underlying lung disease).
- Direct head-to-head comparison with subgroup-specific models using AUC metrics.
Limitations
- Secondary analysis without detailed prospective clinical endpoints or cost-effectiveness assessment.
- Single-cohort context; external validation in independent systems and prospective decision-impact trials are needed.
Future Directions: Prospective impact studies integrating turnaround time, antibiotic initiation/withholding, and outcomes; multi-center external validation and health-economic modeling.
We previously identified a blood-based 4-gene signature that accurately discriminates bacterial from nonbacterial acute respiratory infection (ARI) in 504 hospitalized adults (AUC = 0.90). Here we evaluate how well this global signature performs within subgroups of patients based on underlying lung disease or presence of pneumonia, comparing it to newly developed subgroup-specific signatures assessing whether performance is improved by tailoring unique gene signatures to homogeneous subgroups. Our global gene signature strongly discriminated bacterial from nonbacterial ARI within every clinical subgroup including pneumonia (AUC = 0.77-0.94), and outperformed every subgroup-specific signature (AUC = 0.57-0.90), suggesting broad applicability in adults with ARI.
3. International evidence-based recommendations for point-of-care lung ultrasound : 2025 focused update of the 2012 recommendations.
An international Delphi process reviewed 1,775 publications and produced 83 updated statements on stand‑alone PoCUS, covering ultrasound signs, technique, monitoring, and clinical applications, with ≥80% agreement. The focused update clarifies strengths, limitations, and integration pathways for PoCUS in acute and critical care.
Impact: Standardized, evidence-informed guidance will harmonize PoCUS practice globally and support training, quality, and research priorities in acute respiratory care.
Clinical Implications: Clinicians can apply unified recommendations for acquisition, interpretation, and monitoring, improving diagnostic confidence for conditions such as pneumothorax, interstitial syndromes, effusions, and hemodynamic congestion at the bedside.
Key Findings
- Comprehensive review (1,775 publications) and Delphi consensus yielded 83 statements with ≥80% agreement.
- Domains span ultrasound signs, technical parameters, monitoring strategies, and clinical indications/limitations.
- Focused positioning of PoCUS as a standalone tool with explicit pathways to integrate with other imaging/ultrasound modalities.
Methodological Strengths
- Structured literature synthesis with predefined expert selection and ACCORD-compliant Delphi methodology.
- Explicit agreement thresholds and iterative rounds enhance transparency and reproducibility of consensus.
Limitations
- Consensus and narrative synthesis cannot substitute for randomized trials; variable evidence quality across topics.
- Standalone PoCUS focus may underrepresent integrated multi-organ protocols in complex scenarios.
Future Directions: Prospective multicenter studies to validate PoCUS-driven pathways, competency benchmarks, and outcome impact; integration frameworks with cardiac/abdominal ultrasound and AI decision-support.
PURPOSE: Since the publication of the previous consensus document on point-of-care lung ultrasound (PoCLUS) in 2012, new evidence has emerged. This consensus aims to update current recommendations by focusing on the clinical applications of PoCLUS as a standalone tool, while acknowledging that this focused approach represents a necessary preliminary step toward its effective integration with other organ-specific ultrasound examinations and complementary diagnostic modalities. METHODS: A Delphi-based consensus process was conducted under the supervision of a Steering Committee (five voting members) and a Delphi Committee (two non-voting members). Experts were selected according to strict predefined criteria based on highly impactful scientific output and were assigned to specific domains. A structured literature review covering publications from 2012 to 2025 was performed. Statements were drafted, discussed through multiple online rounds, and iteratively refined. Anonymous voting was conducted for each statement using a predefined agreement threshold (80% full agreement); abstentions were excluded from percentage calculations. The process adhered to ACCORD recommendations. RESULTS: Twenty-one experts participated in the entire process. A total of 1775 new publications were reviewed, including 892 original studies, 62 meta-analyses, 38 guidelines, 162 original studies discussed in the first consensus. New statements were developed across multiple domains addressing ultrasound signs, technical aspects, monitoring strategies, and clinical applications of PoCLUS. Consensus was achieved for 83 statements following iterative discussion and voting rounds. CONCLUSION: This updated consensus provides evidence-based recommendations on the use of PoCLUS in clinical practice, defining its strengths and limitations as a standalone tool and identifying areas requiring further investigation.